The future of iPSCs in toxicology is promising, with ongoing advancements in biotechnology and regenerative medicine. Improvements in reprogramming techniques and differentiation protocols will enhance the accuracy and reliability of iPSC models. The integration of iPSCs with other cutting-edge technologies, such as CRISPR gene editing and high-throughput screening, will further accelerate their application in toxicology. As regulatory agencies recognize the value of iPSC-based models, they may become integral to the drug development and safety assessment processes.
